Evidence Table MULTI.2. Continuous outcomes of MULTI-ARM trials

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
53 ↓ P Mod/sev	**Comedones change (%)**	Short (6)	**Benzoyl peroxide** Percent change: -28	44		**NS**
53 ↓ P Mod/sev	**Comedones change (%)** Vs Placebo	Mid (10)	**Benzoyl peroxide** Percent change: -28	44		**"Sig"**
53 ↓ P Mod/sev	**Comedones change (%)**	Short (6)	**Erythromycin** Percent change: -12	45		**NS**
53 ↓ P Mod/sev	**Comedones change (%)** Vs Placebo	Mid (10)	**Erythromycin** Percent change: -18	45		**"Sig"**
53 ↓ P Mod/sev	**Comedones change (%)**	Short (6)	**Erythromycin + benzoyl peroxide** Percent change: -28	44		**NS**
53 ↓ P Mod/sev	**Comedones change (%)** Vs Placebo	Mid (10)	**Erythromycin + benzoyl peroxide** Percent change: -28	44		**"Sig"**
53 ↓ P Mod/sev	**Comedones change (%)**	Short (6)	**Vehicle** Percent change: -12	44		**NS**
53 ↓ P Mod/sev	**Comedones change (%)**	Mid (10)	**Vehicle** Percent change: -2	44		**NS**
53 ↓ P Mod/sev	**Inflammatory change (%)** Vs Placebo; BP = E	Short (6)	**Benzoyl peroxide** Percent change: -42	44		**"Sig"**
53 ↓ P Mod/sev	**Inflammatory change (%)** Vs Placebo; BP = E	Mid (10)	**Benzoyl peroxide** Percent change: -58	44		**"Sig"**
53 ↓ P Mod/sev	**Inflammatory change (%)** Vs Placebo; E = BP	Short (6)	**Erythromycin** Percent change: -42	45		**"Sig"**
53 ↓ P Mod/sev	**Inflammatory change (%)** Vs Placebo; E = BP	Mid (10)	**Erythromycin** Percent change: -60	45		**"Sig"**
53 ↓ P Mod/sev	**Inflammatory change (%)** Vs BP, E, Placebo	Short (6)	**Erythromycin + benzoyl peroxide** Percent change: -62	44		**"Sig"**
53 ↓ P Mod/sev	**Inflammatory change (%)** Vs BP, E, Placebo	Mid (10)	**Erythromycin + benzoyl peroxide** Percent change: -78	44		**"Sig"**
53 ↓ P Mod/sev	**Inflammatory change (%)**	Short (6)	**Vehicle** Percent change: -15	44		**NS**
53 ↓ P Mod/sev	**Inflammatory change (%)**	Mid (10)	**Vehicle** Percent change: -28	44		**NS**
53 ↓ P Mod/sev	**Papules change (%)** Vs Placebo; BP = E	Short (6)	**Benzoyl peroxide** Percent change: -38	44		**"Sig"**
53 ↓ P Mod/sev	**Papules change (%)** Vs Placebo; BP = E	Mid (10)	**Benzoyl peroxide** Percent change: -54	44		**"Sig"**
53 ↓ P Mod/sev	**Papules change (%)** Vs Placebo; E = BP	Short (6)	**Erythromycin** Percent change: -40	45		**"Sig"**

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
53 ↓ P Mod/sev	**Papules change (%)** Vs Placebo; E = BP	Mid (10)	**Erythromycin** Percent change: -50	45		**"Sig"**
53 ↓ P Mod/sev	**Papules change (%)** Vs E	Short (6)	**Erythromycin + benzoyl peroxide** Percent change: -58	44		**"Sig"**
53 ↓ P Mod/sev	**Papules change (%)** Vs E	Mid (10)	**Erythromycin + benzoyl peroxide** Percent change: -70	44		**"Sig"**
53 ↓ P Mod/sev	**Papules change (%)**	Short (6)	**Vehicle** Percent change: -15	44		**NS**
53 ↓ P Mod/sev	**Papules change (%)**	Mid (10)	**Vehicle** Percent change: -30	44		**NS**
53 ↓ P Mod/sev	**Pustules change (%)** Vs Placebo; BP = E = E + BP	Short (6)	**Benzoyl peroxide** Percent change: -55	44		**"Sig"**
53 ↓ P Mod/sev	**Pustules change (%)** Vs Placebo	Mid (10)	**Benzoyl peroxide** Percent change: -70	44		**"Sig"**
53 ↓ P Mod/sev	**Pustules change (%)** Vs Placebo; E = BP = E + BP	Short (6)	**Erythromycin** Percent change: -48	45		**"Sig"**
53 ↓ P Mod/sev	**Pustules change (%)** Vs Placebo	Mid (10)	**Erythromycin** Percent change: -70	45		**"Sig"**
53 ↓ P Mod/sev	**Pustules change (%)** Vs Placebo; E + BP = BP = E	Short (6)	**Erythromycin + benzoyl peroxide** Percent change: -80	44		**"Sig"**
53 ↓ P Mod/sev	**Pustules change (%)** Vs Placebo	Mid (10)	**Erythromycin + benzoyl peroxide** Percent change: -90	44		**"Sig"**
53 ↓ P Mod/sev	**Pustules change (%)**	Short (6)	**Vehicle** Percent change: -10	44		**NS**
53 ↓ P Mod/sev	**Pustules change (%)**	Mid (10)	**Vehicle** Percent change: -28	44		**NS**
97 ↑ P Mild/mod	**Total lesions change (%)** With respect to placebo	Short (4)	**Benzoyl peroxide** Percent change: -37	48	M	**0.001**
97 ↑ P Mild/mod	**Total lesions change (%)** With respect to placebo	Short (4)	**Benzoyl peroxide + chlorhydroxyquinoline** Percent change: -56	54	M	**NS**
97 ↑ P Mild/mod	**Total lesions change (%)** With respect to placebo	Short (4)	**Vehicle** Percent change: 6	48	M	**0.001**
108 P Mild/mod/sev	**Medication used (mg/kg)**	Mid (10)	**Erythromycin + zinc (gel) + Placebo (oral)** Raw measure: 27	39		

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
108 P Mild/mod/sev	**Medication used (mg/kg)**	Mid (10)	**Erythromycin + zinc (liquid) + placebo (oral)** Raw measure: 86	40		
108 P Mild/mod/sev	**Medication used (mg/kg)**	Mid (10)	**Tetracycline (oral) + placebo (topical)** Raw measure: 463	39		
108 P Mild/mod/sev	**Papules change (%)** Gel = tet liq > pl	Short (6)	**Erythromycin + zinc (gel) + Placebo (oral)** Percent change: -39 (50.)	39		**0.05**
108 P Mild/mod/sev	**Papules change (%)** EZ liquid, gel = Tet	Mid (10)	**Erythromycin + zinc (gel) + Placebo (oral)** Percent change: -45 (50.)	39		**0.05**
108 P Mild/mod/sev	**Papules change (%)** Gel = tet liq > pl	Short (6)	**Erythromycin + zinc (liquid) + placebo (oral)** Percent change: -52 (50.)	40		**0.001**
108 P Mild/mod/sev	**Papules change (%)** EZ liquid, gel = Tet	Mid (10)	**Erythromycin + zinc (liquid) + placebo (oral)** Percent change: -58 (50.)	40		**0.001**
108 P Mild/mod/sev	**Papules change (%)** Gel = tet liq > pl	Short (6)	**Placebo (topical) + placebo (oral)** Percent change: -23 (50.)	31		
108 P Mild/mod/sev	**Papules change (%)** EZ liquid, gel = Tet	Mid (10)	**Placebo (topical) + placebo (oral)** Percent change: -25 (50.)	31		**NS**
108 P Mild/mod/sev	**Papules change (%)** Gel = tet liq > pl	Short (6)	**Tetracycline (oral) + placebo (topical)** Percent change: -55 (50.)	39		
108 P Mild/mod/sev	**Papules change (%)** EZ liquid, gel = Tet	Mid (10)	**Tetracycline (oral) + placebo (topical)** Percent change: -51 (50.)	39		**0.01**

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
108 P Mild/mod/sev	**Severity change (Cook)**	Short (6)	**Erythromycin + zinc (gel) + Placebo (oral)** Raw measure: -33 (50.)	39		**0.01**
108 P Mild/mod/sev	**Severity change (Cook)**	Short (6)	**Erythromycin + zinc (liquid) + placebo (oral)** Raw measure: -39 (50.)	40		**0.001**
108 P Mild/mod/sev	**Severity change (Cook)**	Short (6)	**Placebo (topical) + placebo (oral)** Raw measure: 14 (50.)	31		**NS**
108 P Mild/mod/sev	**Severity change (Cook)**	Short (6)	**Tetracycline (oral) + placebo (topical)** Raw measure: -35 (50.)	39		**0.01**
108 P Mild/mod/sev	**Severity change (Cook %)**	Mid (10)	**Erythromycin + zinc (gel) + Placebo (oral)** Raw measure: -33 (50.)	39		**0.01**
108 P Mild/mod/sev	**Severity change (Cook %)**	Mid (10)	**Erythromycin + zinc (liquid) + placebo (oral)** Raw measure: -46 (50.)	40		**0.001**
108 P Mild/mod/sev	**Severity change (Cook %)**	Mid (10)	**Placebo (topical) + placebo (oral)** Raw measure: -7 (50.)	31		
108 P Mild/mod/sev	**Severity change (Cook %)**	Mid (10)	**Tetracycline (oral) + placebo (topical)** Raw measure: -32 (50.)	39		**0.01**
109 ↓ P Mod	**Total lesions (count)**	Mid (12)	**Benzoyl peroxide (contingent contract)** Change*: -8	*21	0.0001	**0.04**
109 ↓ P Mod	**Total lesions (count)**	Mid (12)	**Benzoyl peroxide (non-contingent contract)** Change*: -13	*21	0.0001	**0.04**
109 ↓ P Mod	**Total lesions (count)**	Mid (12)	**Benzoyl peroxide (self monitoring)** Change*: -15	*21	0.0001	**0.04**
109 ↓ P Mod	**Total lesions (count)**	Mid (12)	**Untreated** Change*: 0	*21	M	**NS**

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
119 ↑ P s	**Irritation (score)**	Short (3)	**Adapalene** Raw measure: 0	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Adapalene** Raw measure: 0 (0.38)	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Petrolatum** Raw measure: 0 (0.31)	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Petrolatum** Raw measure: 0	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.01% gel)** Raw measure: 2 (0.37)	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.01% gel)** Raw measure: 3	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.025% cream)** Raw measure: 2	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.025% cream)** Raw measure: 2 (0.37)	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.025% gel)** Raw measure: 3	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.025% gel)** Raw measure: 2 (0.42)	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.05% cream)** Raw measure: 2 (0.29)	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.05% cream)** Raw measure: 3	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.1% cream)** Raw measure: 2 (0.34)	28	M	**M**
119 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.1% cream)** Raw measure: 3	28	M	**M**
120 ↑ P s	**Irritation (score)**	Short (3)	**Adapalene** Raw measure: 0	27	M	**M**
120 ↑ P s	**Irritation (score)**	Short (3)	**Petrolatum** Raw measure: 0	27	M	**M**
120 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0 .1% cream)** Raw measure: 2	27	M	**M**
120 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.025% cream)** Raw measure: 2	27	M	**M**
120 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.05% cream)** Raw measure: 2	27	M	**M**

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
120 ↑ P s	**Irritation (score)**	Short (3)	**Tretinoin (0.1% gel)** Raw measure: 2	27	M	**M**
120 ↑ P s	**Local reactions/Irritation (Cumulative score)**	Short (3)	**Adapalene** Raw measure: 0	27	M	**M**
120 ↑ P s	**Local reactions/Irritation (Cumulative score)**	Short (3)	**Petrolatum** Raw measure: 0	27	M	**M**
120 ↑ P s	**Local reactions/Irritation (Cumulative score)**	Short (3)	**Tretinoin (0 .1% cream)** Raw measure: 2	27	M	**M**
120 ↑ P s	**Local reactions/Irritation (Cumulative score)**	Short (3)	**Tretinoin (0.025% cream)** Raw measure: 1	27	M	**M**
120 ↑ P s	**Local reactions/Irritation (Cumulative score)**	Short (3)	**Tretinoin (0.05% cream)** Raw measure: 1	27	M	**M**
120 ↑ P s	**Local reactions/Irritation (Cumulative score)**	Short (3)	**Tretinoin (0.1% gel)** Raw measure: 1	27	M	**M**
149 ↓ P Mild/mod/sev	**Time to favorable status (mean weeks)**	Mid (10)	**Benzoyl peroxide (5%)** Raw measure: 7	50		**NS**
149 ↓ P Mild/mod/sev	**Time to favorable status (mean weeks)**	Mid (10)	**Benzoyl peroxide (10%)** Raw measure: 6	50		**NS**
149 ↓ P Mild/mod/sev	**Time to favorable status (mean weeks)**	Mid (10)	**Tretinoin** Raw measure: 7	50		**NS**
156 ↓ P Mod/sev	**Severity (Michaelsson)**	Mid (12)	**Cimetidine [men]** Raw measure: 60 (18.)	9	0.01	**M**
156 ↓ P Mod/sev	**Severity (Michaelsson)**	Mid (12)	**Cimetidine [women]** Raw measure: 44 (29.)	16	0.001	**M**
156 ↓ P Mod/sev	**Severity (Michaelsson)**	Mid (12)	**Spironolactone [men]** Raw measure: 48 (30.)	10	M	**M**
156 ↓ P Mod/sev	**Severity (Michaelsson)**	Mid (12)	**Spironolactone [women]** Raw measure: 32 (22.4)	15	M	**M**

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
177 ↑ P	**Face severity (Jaffe)**	Mid (12)	**Benzoyl peroxide** Raw measure: -3 (0.12)	28	0.001	**M**
177 ↑ P	**Face severity (Jaffe)**	Mid (12)	**Hydroxyquinoline + benzoyl peroxide** Raw measure: -5 (0.17)	25	0.0001	**M**
177 ↑ P	**Face severity (Jaffe)**	Mid (12)	**Vehicle** Raw measure: -3 (0.1)	27	0.001	**M**
214 ↑ P Mod	**Inflammatory change (%)**	Mid (11)	**Benzoyl peroxide** Percent change: -39 (4.)	92	M	**0.02**
214 ↑ P Mod	**Inflammatory change (%)**	Mid (11)	**Clindamycin** Percent change: -35 (5.)	89	M	**0.02**
214 ↑ P Mod	**Inflammatory change (%)**	Mid (11)	**Clindamycin + benzoyl peroxide** Percent change: -61 (3.)	95	M	**0.02**
214 ↑ P Mod	**Inflammatory change (%)**	Mid (11)	**Vehicle** Percent change: 5 (7.)	58	M	**NS**
214 ↑ P Mod	**Non-inflammatory change (%)**	Mid (11)	**Benzoyl peroxide** Percent change: -30 (4.)	92	M	**0.005**
214 ↑ P Mod	**Non-inflammatory change (%)** .01 vs clinda alone	Mid (11)	**Clindamycin** Percent change: -9 (6.)	89	M	**0.04**
214 ↑ P Mod	**Non-inflammatory change (%)** .01 vs clinda alone	Mid (11)	**Clindamycin + benzoyl peroxide** Percent change: -36 (4.)	95	M	**0.004**
214 ↑ P Mod	**Non-inflammatory change (%)**	Mid (11)	**Vehicle** Percent change: -11 (8.)	58	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)**	Short (4)	**Clindamycin hydrochloride (E-solve®)** Percent change: -51 (34.)	23	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)** Vs.clindamycin hydrochloride(Ionax®)	Mid (8)	**Clindamycin hydrochloride (E-solve®)** Percent change: -75 (22.)	23	M	**0.001**
229 ↑ P s Mod/sev	**Inflammatory change (%)**	Short (4)	**Clindamycin hydrochloride (Ionax®)** Percent change: -70 (18.)	16	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)** Vs.clindamycin hydrochloride(E-solve®)	Mid (8)	**Clindamycin hydrochloride (Ionax®)** Percent change: -83 (19.)	16	M	**0.001**
229 ↑ P s Mod/sev	**Inflammatory change (%)**	Short (4)	**Clindamycin phosphate (E-solve®)** Percent change: 65 (32.)	16	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)** Vs.clindamycin phosphate(Ionax®)	Mid (8)	**Clindamycin phosphate (E-solve®)** Percent change: -83 (22.)	17	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)**	Short (4)	**Clindamycin phosphate (Ionax®)** Percent change: -66 (18.)	21	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)** Vs. Clindamycin phosphate (e-solve)	Mid (8)	**Clindamycin phosphate (Ionax®)** Percent change: -81 (16.)	20	M	**NS**

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
229 ↑ P s Mod/sev	**Inflammatory change (%)**	Short (4)	**E-solve®** Percent change: -55 (37.)	17	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)** Vs. Ionax®	Mid (8)	**E-solve®** Percent change: -78 (19.)	19	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)**	Short (4)	**Ionax®** Percent change: -63 (28.)	23	M	**NS**
229 ↑ P s Mod/sev	**Inflammatory change (%)** Vs. E-solve®	Mid (8)	**Ionax®** Percent change: -76 (18.)	23	M	**NS**
233 ↑ P Mod/sev	**Severity change (Michaelsson %)**	Short (4)	**Vehicle** Raw measure: -25 (30.)	14	M	**NS**
233 ↑ P Mod/sev	**Severity change (Michaelsson %)**	Short (4)	**Vitamin A palmitate** Raw measure: -30 (27.)	14	M	**NS**
233 ↑ P Mod/sev	**Severity change (Michaelsson %)**	Short (4)	**Zinc sulfate** Raw measure: -64 (15.)	15	M	**NS**
233 ↑ P Mod/sev	**Severity change (Michaelsson %)**	Short (4)	**Zinc sulfate + Vitamin A palmitate** Raw measure: -58 (15.)	18	M	**NS**
239 ↓ P Mod/sev	**Non-inflammatory change (%)**	Mid (8)	**Aluminum oxide** Percent change: -19	10		**NS**
266 ↑ P Mod	**Inflammatory (count)**	Short (6)	**Placebo** Change*: -4	15	NS	
266 ↑ P Mod	**Inflammatory (count)**	Short (6)	**Shankhabhasma vah** Change*: -7	14	NS	
266 ↑ P Mod	**Inflammatory (count)**	Short (6)	**Sookshama triphala** Change*: -4	16	NS	
266 ↑ P Mod	**Inflammatory (count)**	Short (6)	**Sunder vati** Change*: -14	20	0.01	
266 ↑ P Mod	**Inflammatory (count)**	Short (6)	**Thiostanin** Change*: -4	17	NS	
266 ↑ P Mod	**Non-inflammatory (count)**	Short (6)	**Placebo** Raw count: 46 (2.8)	15	NS	
266 ↑ P Mod	**Non-inflammatory (count)**	Short (6)	**Shankhabhasma vah** Raw count: 46 (2.8)	14	NS	
266 ↑ P Mod	**Non-inflammatory (count)**	Short (6)	**Sookshama triphala** Raw count: 46 (2.)	16	NS	
266 ↑ P Mod	**Non-inflammatory (count)**	Short (6)	**Sunder vati** Raw count: 35 (4.)	20	0.01	

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
266 ↑ P Mod	**Non-inflammatory (count)**	Short (6)	**Thiostanin** Raw count: 45 (4.)	17	NS	
302 ↓ P s Mild	**Burning**	Mid (10)	**Tretinoin (0.01%)** Raw measure: 1	20		**NS**
302 ↓ P s Mild	**Burning**	Mid (10)	**Tretinoin (0.025%)** Raw measure: 2	10		**NS**
302 ↓ P s Mild	**Burning**	Mid (10)	**Tretinoin (0.05%)** Raw measure: 2	10		**NS**
302 ↓ P s Mild	**Erythema** Only significant compared to patients asses .025%	Mid (10)	**Tretinoin (0.01%)** Raw measure: 1	20		
302 ↓ P s Mild	**Erythema**	Mid (10)	**Tretinoin (0.025%)** Raw measure: 2	10		**NS**
302 ↓ P s Mild	**Erythema**	Mid (10)	**Tretinoin (0.05%)** Raw measure: 1	10		**NS**
302 ↓ P s Mild	**Scaling**	Mid (10)	**Tretinoin (0.01%)** Raw measure: 1	20		
302 ↓ P s Mild	**Scaling** Only significant in does assess with respect to .025	Mid (10)	**Tretinoin (0.025%)** Raw measure: 2	10	M	**0.05**
302 ↓ P s Mild	**Scaling**	Mid (10)	**Tretinoin (0.05%)** Raw measure: 2	10		**NS**
302 ↓ P s Mild	**Comedones (count)**	Mid (10)	**Tretinoin (0.01%)** Change*: -7	20	M	**M**
302 ↓ P s Mild	**Comedones (count)**	Mid (10)	**Tretinoin combined** Change*: -7	20		**NS**
302 ↓ P s Mild	**Inflammatory (count)**	Mid (10)	**Tretinoin (0.01%)** Change*: -4	20		**0.05**
302 ↓ P s Mild	**Inflammatory (count)**	Mid (10)	**Tretinoin combined** Change*: -7	20	M	**M**
302 ↓ P s Mild	**Comedones (improvement)**	Short (6)	**Tretinoin (0.01%)** Raw measure: 13	20		**0.05**
302 ↓ P s Mild	**Comedones (improvement)**	Mid (10)	**Tretinoin (0.01%)** Raw measure: 14	20	M	**M**
302 ↓ P s Mild	**Comedones (improvement)**	Short (6)	**Tretinoin combined** Raw measure: 10	20		**0.05**
302 ↓ P s Mild	**Comedones (improvement)**	Mid (10)	**Tretinoin combined** Raw measure: 12	20	M	**M**

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Trial	Continuous Outcome Name (Units) Comments re Between P-value	Follow up	Treatment Data Type: Mean (SD)	SS	Within P	Between P-value
302 ↓ P s Mild	**Inflammatory (improvement)**	Short (6)	**Tretinoin (0.01%)** Raw measure: 13	20	M	**M**
302 ↓ P s Mild	**Inflammatory (improvement)**	Mid (10)	**Tretinoin (0.01%)** Raw measure: 14	20		**0.05**
302 ↓ P s Mild	**Inflammatory (improvement)**	Short (6)	**Tretinoin combined** Raw measure: 12	20	M	**M**
302 ↓ P s Mild	**Inflammatory (improvement)**	Mid (10)	**Tretinoin combined** Raw measure: 13	20		**0.05**
349 ↓ P Mild/mod	**Total change (%)** 2-factor ANOVA	Mid (8)	**Ibuprofen + placebo** Percent change: -26 (52.)	14		**0.05**
349 ↓ P Mild/mod	**Total change (%)** 2-factor ANOVA	Mid (8)	**Placebo** Percent change: -16 (44.)	16		**NS**
349 ↓ P Mild/mod	**Total change (%)** 2-factor ANOVA	Mid (8)	**Tetracycline + placebo** Percent change: -26 (36.)	15		**0.05**
349 ↓ P Mild/mod	**Total lesion (count)**	Short (4)	**Ibuprofen + placebo** Change*: -8	14		
349 ↓ P Mild/mod	**Total lesion (count)**	Short (4)	**Placebo** Change*: -1	16		
349 ↓ P Mild/mod	**Total lesion (count)**	Short (4)	**Tetracycline + placebo** Change*: -3	15		

TRIAL: ↑↓refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.